INT173578

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.44
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 10
Disease Relevance 6.29
Pain Relevance 1.15

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (CTSK) extracellular space (CTSK) lysosome (CTSK)
cytoplasm (CTSK)
Anatomy Link Frequency
joint 1
skin 1
osteoclast 1
CTSK (Homo sapiens)
Pain Link Frequency Relevance Heat
rheumatoid arthritis 155 96.64 Very High Very High Very High
metalloproteinase 64 92.48 High High
cytokine 11 77.80 Quite High
Inflammation 32 61.52 Quite High
Osteoarthritis 16 52.32 Quite High
cva 33 48.80 Quite Low
Leflunomide 15 24.64 Low Low
Rheumatism 5 23.20 Low Low
methotrexate 10 16.52 Low Low
Potency 14 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hypercalcemia 115 99.92 Very High Very High Very High
Osteopetrosis 77 99.92 Very High Very High Very High
Targeted Disruption 10 98.72 Very High Very High Very High
Congenital Anomalies 12 97.52 Very High Very High Very High
Metastasis 19 97.08 Very High Very High Very High
Systemic Sclerosis 3 97.08 Very High Very High Very High
Rheumatoid Arthritis 155 96.64 Very High Very High Very High
Breast Cancer 62 96.44 Very High Very High Very High
Acro-osteolysis 5 95.84 Very High Very High Very High
Growth Problems 9 95.20 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Inhibition of cathepsin K may therefore prevent bone resorption, as could be demonstrated in bone metastasis from breast cancer [16].
Negative_regulation (Inhibition) of cathepsin K associated with breast cancer, hypercalcemia and metastasis
1) Confidence 0.44 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1064888 Disease Relevance 1.90 Pain Relevance 0.24
According to this, they developed a peptide aldehyde inhibitor of cathepsin K that inhibits osteoclast-mediated bone resorption in foetal rat long bone organ cultures and even in a human osteoclast-mediated assay in vitro.
Negative_regulation (inhibitor) of cathepsin K in osteoclast associated with hypercalcemia
2) Confidence 0.32 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1064888 Disease Relevance 0.63 Pain Relevance 0.11
Inhibition of cathepsin K may therefore be a new target for preventing bone erosion and joint destruction in rheumatoid arthritis.
Negative_regulation (Inhibition) of cathepsin K in joint associated with rheumatoid arthritis
3) Confidence 0.32 Published 2005 Journal Arthritis Res Ther Section Abstract Doc Link PMC1064888 Disease Relevance 0.61 Pain Relevance 0.18
Furthermore, structure activity studies on a series of reversible ketoamide-based inhibitors of cathepsin K have led to the identification of potent and selective inhibitors [28].
Negative_regulation (inhibitors) of cathepsin K
4) Confidence 0.32 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1064888 Disease Relevance 0.58 Pain Relevance 0.13
GH and WW developed the cathepsin K ELISA kit.
Negative_regulation (developed) of cathepsin K
5) Confidence 0.32 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1064888 Disease Relevance 0.65 Pain Relevance 0.26
Inhibition of cathepsin K prevents matrix degradation [50,51], and deletion of the cathepsin K gene in mice leads to osteopetrosis [52,53].
Negative_regulation (Inhibition) of cathepsin K associated with osteopetrosis
6) Confidence 0.22 Published 2009 Journal Orphanet J Rare Dis Section Body Doc Link PMC2654865 Disease Relevance 0.66 Pain Relevance 0.05
Odanacatib is a highly selective, nonlysosomotropic cathepsin K inhibitor, structurally distinct from other inhibitors that occasionally induced “morphea-like” skin changes.
Negative_regulation (inhibitor) of cathepsin K in skin associated with systemic sclerosis
7) Confidence 0.07 Published 2010 Journal Osteoporos Int Section Body Doc Link PMC2931762 Disease Relevance 0.26 Pain Relevance 0
Other potentially useful inhibitors of bone resorption include cathepsin K inhibitors, src kinase inhibitors, integrin inhibitors, chloride channel inhibitors, and PTHrP antibodies.
Negative_regulation (inhibitors) of cathepsin K associated with hypercalcemia
8) Confidence 0.07 Published 2010 Journal Osteoporos Int Section Body Doc Link PMC2931762 Disease Relevance 0.26 Pain Relevance 0
Cathepsin K inhibitors are the only ones of these candidate drugs currently in phase 3 development.
Negative_regulation (inhibitors) of Cathepsin K
9) Confidence 0.07 Published 2010 Journal Osteoporos Int Section Body Doc Link PMC2931762 Disease Relevance 0.16 Pain Relevance 0
When cathepsin K is deficient, bone resorption is impared.
Negative_regulation (deficient) of cathepsin K associated with hypercalcemia
10) Confidence 0.05 Published 2003 Journal Arthritis Res Ther Section Body Doc Link PMC154424 Disease Relevance 0.56 Pain Relevance 0.18

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox